FOLH1 and prostate cancer: A recent multicenter study that enrolled 348 prostate cancer patients demonstrated unspecific bone uptake of [18F]F-PSMA-1007 in 217 (51.4%) patients, of which in 80 (44.7%) patients it was crucial for further therapeutic approaches and was considered clinically important [40].